Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000929638-25-001428
Filing Date
2025-04-01
Accepted
2025-04-01 21:40:20
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 10617
  Complete submission text file 0000929638-25-001428.txt   12310
Mailing Address 12790 EL CAMINO REAL, SUITE 200 SAN DIEGO CA 92130
Business Address 12790 EL CAMINO REAL, SUITE 200 SAN DIEGO CA 92130 (858) 945-2393
Ventyx Biosciences, Inc. (Subject) CIK: 0001851194 (see all company filings)

EIN.: 832996852 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-92974 | Film No.: 25801789
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 500 WEST PUTNAM AVE SUITE 400 GREENWICH CT 06830
Business Address 500 WEST PUTNAM AVE SUITE 400 GREENWICH CT 06830 2126885100
NSV Partners III LP (Filed by) CIK: 0001890004 (see all company filings)

EIN.: 371941525 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A